Stay Up to Date
Breaking News,
Updates, & More
Click Here to
Subscribe

Managing Immune-Related Toxicities in Patients with Lung Cancer

TOP - May 2017, Vol 10, No 2 - Lung Cancer
Meg Barbor, MPH

Vienna, Austria—Toxicities related to immunotherapies approved for the treatment of patients with non–small-cell lung cancer (NSCLC) are uncommon but can be life-threatening, according to Marianne Davies, DNP, RN, CNS, ACNP, AOCNP, Assistant Professor, Yale University School of Nursing and Thoracic Oncology Nurse Practitioner, Yale Comprehensive Cancer Center, New Haven, CT.

Immune-related toxicities in patients with NSCLC can be traced back to the mechanism of action of immune checkpoint inhibitors. Once activation of the immune system occurs, it cannot be confined to antitumor effects or solely to the tumor itself. Amplification of the immune system can lead to unrestrained T-cell activity and an attack on healthy cells.

Dr Davies said the basis of immune-related adverse events is inflammation, meaning any “‑itis” or “‑opathy.”

“Most patients have complex co­morbidities in these cases, so the first rule of thumb is to rule out other causes of adverse events. And, in many cases, it’s a diagnosis of exclusion, unless you have biopsy-confirmed immune-related adverse events,” she cautioned.

At the International Association for the Study of Lung Cancer 17th World Conference on Lung Cancer, Dr Davies highlighted the importance of educating all members of the healthcare team on the rapid diagnosis and treatment of immune-related adverse events.

Toxicities Related to Checkpoint Inhibitors for NSCLC

Three checkpoint inhibitors are currently approved for the treatment of patients with NSCLC. Nivolumab is approved for the treatment of metastatic NSCLC after failure of a platinum-based chemotherapy regimen; it can be prescribed, independent of the patient’s PD-L1 status. Pembrolizumab is approved for first-line treatment of metastatic NSCLC if PD-L1 expression is ≥50%, and for second-line treatment after lack of response to a platinum-based chemotherapy regimen when PD-L1 expression is ≥1%. Atezolizumab is approved for the treatment of metastatic NSCLC after failure of a platinum-based chemotherapy regimen, independent of PD-L1 status.

Pneumonitis, colitis, and rash are the most common toxicities associated with immunotherapy for NSCLC. Ipilimu­mab, an anti-cytotoxic T-lymphocyte–associated protein 4 inhibitor, is not yet approved for the treatment of NSCLC. However, Dr Davies predicts an increase in the use of combination treatment with ipilimumab and nivolumab, which is often accompanied by a significantly higher incidence of colitis and rash than is seen with nivolumab, pembro­lizumab, and atezolizumab.

Patterns of Immune-Related Adverse Events

There is extreme variability in immune-related adverse event onset, but skin toxicities tend to occur earliest, followed by gastrointestinal toxicities and lab abnormalities. Toxicities may affect ≥1 organ systems (eg, pulmonary, endocrine, renal, gastrointestinal, cardiac, ocular), and can range from asymptomatic to severe and life-threatening. There is a suggested dose-dependency and/or cumulative effect, and toxicities are increased in patients being treated with combinations of immunotherapies, chemotherapy, or radiation.

Dr Davies stressed the importance of using a treatment algorithm to understand the signs and symptoms of all organ-specific, immune-related adverse events, as well as the proper management of these toxicities based on improvement or progression. For example, a patient with pneumonitis would likely present with symptoms such as dyspnea, cough, wheezing, or chest pain. The patient’s oxygen saturation should be measured to rule out infectious causes, lymphangitic spread, and pulmonary embolism, and, once identified, the toxicity should be graded. If the toxicity is grade 1 (radiographic changes only), consider withholding treatment, she advised. When the toxicity is grade 2 (mild-to-moderate symptoms), withhold treatment, provide supportive care, and initiate steroids. If the patient presents with grade ≥3 toxicity, in addition to steroid treatment, oxygen support, and use of albuterol, therapy should be permanently discontinued.

Dr Davies said most immune-related dermatologic toxicities are grade 1 or 2, and can be managed with topical steroids and anti-itch creams. However, if a rash or other skin toxicity reaches grade 3 or 4, consider permanent discontinuation of therapy.

Regarding gastrointestinal toxicities, ensure that patients know the difference between diarrhea and colitis, she said. If toxicity reaches grade 2 (4-6 stools greater than baseline abdominal pain), withhold treatment until toxicity decreases to grade 1, and discontinue if supportive therapy and steroids do not lessen the severity. Tapering of steroids should be under the direct supervision of the oncology team for a minimum of 4 to 6 weeks.

“If you taper too quickly, patients can have a rebound and a more significant toxicity,” she added.

Additional anti-immunosuppressants may be necessary if patients do not respond to steroids. In the case of hyperthyroidism, hypothyroidism, or thyroiditis, Dr Davies said most patients can continue with therapy, barring the presence of significant hemodynamic compromise.

Use of standardized algorithms is beneficial to the management of immune-related adverse events, but, according to Dr Davies, the decision to restart treatment is not always clear. However, despite the toxicities associated with immunotherapy, reinitiation of treatment may be possible with optimal management.

Related Items
Preserving Sexual Function in Women After Cancer Treatment
Meg Barbor, MPH
TON - August 2019, Vol 12, No 4 published on August 6, 2019 in ONS
What to Expect with USP 800: Implementing Safe Handling Practices of Hazardous Drugs
Meg Barbor, MPH
TON - August 2019, Vol 12, No 4 published on August 6, 2019 in ONS
Creating a Compassionate Workplace: Promoting Civility in Oncology Nursing
Meg Barbor, MPH
TON - August 2019, Vol 12, No 4 published on August 6, 2019 in ONS
Assessing the Value of Digital Health Technology in Cancer Care
Meg Barbor, MPH
TON - August 2019, Vol 12, No 4 published on August 6, 2019 in ACCC
Repotrectinib, an Investigational TKI, Induces Response in ROS1-Fusion–Positive NSCLC
Wayne Kuznar
TOP - August 2019, Vol 12, No 3 published on July 29, 2019 in Lung Cancer
The Evolving Role of Precision Medicine in Clinical Practice
Meg Barbor, MPH
TOP - August 2019, Vol 12, No 3 published on July 29, 2019 in HOPA
Lorbrena (Lorlatinib) Approved for the Treatment of Metastatic Non–Small-Cell Lung Cancer with ALK Mutation
Loretta Fala, Medical Writer
2019 Fourth Annual Oncology Guide to New FDA Approvals published on June 5, 2019 in FDA Approvals, Lung Cancer
Vizimpro (Dacomitinib) Approved for First-Line Treatment of Metastatic Non–Small-Cell Lung Cancer with EGFR Mutation
Loretta Fala, Medical Writer
2019 Fourth Annual Oncology Guide to New FDA Approvals published on June 5, 2019 in FDA Approvals, Lung Cancer
New HOPA Committee Aims to Improve Patient Outreach Services
Meg Barbor, MPH
TOP - May 2019, Vol 12, No 2 published on May 13, 2019 in HOPA
Current Strategies in the Management of CINV
Meg Barbor, MPH
TOP - May 2019, Vol 12, No 2 published on May 13, 2019 in HOPA
Last modified: May 18, 2017